Cargando…
NK Cell-Based Immunotherapy in Cancer Metastasis
Metastasis represents the leading cause of cancer-related death mainly owing to the limited efficacy of current anticancer therapies on advanced malignancies. Although immunotherapy is rendering promising results in the treatment of cancer, many adverse events and factors hampering therapeutic effic...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357056/ https://www.ncbi.nlm.nih.gov/pubmed/30597841 http://dx.doi.org/10.3390/cancers11010029 |
_version_ | 1783391706383646720 |
---|---|
author | Lorenzo-Herrero, Seila López-Soto, Alejandro Sordo-Bahamonde, Christian Gonzalez-Rodriguez, Ana P Vitale, Massimo Gonzalez, Segundo |
author_facet | Lorenzo-Herrero, Seila López-Soto, Alejandro Sordo-Bahamonde, Christian Gonzalez-Rodriguez, Ana P Vitale, Massimo Gonzalez, Segundo |
author_sort | Lorenzo-Herrero, Seila |
collection | PubMed |
description | Metastasis represents the leading cause of cancer-related death mainly owing to the limited efficacy of current anticancer therapies on advanced malignancies. Although immunotherapy is rendering promising results in the treatment of cancer, many adverse events and factors hampering therapeutic efficacy, especially in solid tumors and metastases, still need to be solved. Moreover, immunotherapeutic strategies have mainly focused on modulating the activity of T cells, while Natural Killer (NK) cells have only recently been taken into consideration. NK cells represent an attractive target for cancer immunotherapy owing to their innate capacity to eliminate malignant tumors in a non-Major Histocompatibility Complex (MHC) and non-tumor antigen-restricted manner. In this review, we analyze the mechanisms and efficacy of NK cells in the control of metastasis and we detail the immunosubversive strategies developed by metastatic cells to evade NK cell-mediated immunosurveillance. We also share current and cutting-edge clinical approaches aimed at unleashing the full anti-metastatic potential of NK cells, including the adoptive transfer of NK cells, boosting of NK cell activity, redirecting NK cell activity against metastatic cells and the release of evasion mechanisms dampening NK cell immunosurveillance. |
format | Online Article Text |
id | pubmed-6357056 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63570562019-02-05 NK Cell-Based Immunotherapy in Cancer Metastasis Lorenzo-Herrero, Seila López-Soto, Alejandro Sordo-Bahamonde, Christian Gonzalez-Rodriguez, Ana P Vitale, Massimo Gonzalez, Segundo Cancers (Basel) Review Metastasis represents the leading cause of cancer-related death mainly owing to the limited efficacy of current anticancer therapies on advanced malignancies. Although immunotherapy is rendering promising results in the treatment of cancer, many adverse events and factors hampering therapeutic efficacy, especially in solid tumors and metastases, still need to be solved. Moreover, immunotherapeutic strategies have mainly focused on modulating the activity of T cells, while Natural Killer (NK) cells have only recently been taken into consideration. NK cells represent an attractive target for cancer immunotherapy owing to their innate capacity to eliminate malignant tumors in a non-Major Histocompatibility Complex (MHC) and non-tumor antigen-restricted manner. In this review, we analyze the mechanisms and efficacy of NK cells in the control of metastasis and we detail the immunosubversive strategies developed by metastatic cells to evade NK cell-mediated immunosurveillance. We also share current and cutting-edge clinical approaches aimed at unleashing the full anti-metastatic potential of NK cells, including the adoptive transfer of NK cells, boosting of NK cell activity, redirecting NK cell activity against metastatic cells and the release of evasion mechanisms dampening NK cell immunosurveillance. MDPI 2018-12-28 /pmc/articles/PMC6357056/ /pubmed/30597841 http://dx.doi.org/10.3390/cancers11010029 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lorenzo-Herrero, Seila López-Soto, Alejandro Sordo-Bahamonde, Christian Gonzalez-Rodriguez, Ana P Vitale, Massimo Gonzalez, Segundo NK Cell-Based Immunotherapy in Cancer Metastasis |
title | NK Cell-Based Immunotherapy in Cancer Metastasis |
title_full | NK Cell-Based Immunotherapy in Cancer Metastasis |
title_fullStr | NK Cell-Based Immunotherapy in Cancer Metastasis |
title_full_unstemmed | NK Cell-Based Immunotherapy in Cancer Metastasis |
title_short | NK Cell-Based Immunotherapy in Cancer Metastasis |
title_sort | nk cell-based immunotherapy in cancer metastasis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357056/ https://www.ncbi.nlm.nih.gov/pubmed/30597841 http://dx.doi.org/10.3390/cancers11010029 |
work_keys_str_mv | AT lorenzoherreroseila nkcellbasedimmunotherapyincancermetastasis AT lopezsotoalejandro nkcellbasedimmunotherapyincancermetastasis AT sordobahamondechristian nkcellbasedimmunotherapyincancermetastasis AT gonzalezrodriguezanap nkcellbasedimmunotherapyincancermetastasis AT vitalemassimo nkcellbasedimmunotherapyincancermetastasis AT gonzalezsegundo nkcellbasedimmunotherapyincancermetastasis |